Want to Calculate Fair Value?
Enter Stock | Calculate Fair Value
📥 Value-Trades has Launched Excel Tool. Click here to Learn More.

Limited details are visible to free users.
Get the paid version for Just $5.00/month or $55.00/year (save 13%)
- ad-free and packed with premium features.

Click MSFT to see all details.

Advertisement
Stock: TXG
Book Value Per Share: $6.21
EPS: $0
EBITDA: $-97 M
Dividend Per Share: $None
Dividend Yield: 0.00 %
Dividend Payout Ratio: 0%
Market Cap: 2.070 B
Return on Assets (TTM): -8.42%
Price To Sales Ratio TTM: 3.226
Price To Book Ratio: 2.56
PEG Ratio: None
EV To EBITDA: -40.69
P/E Ratio: None
Forward P/E Ratio: 196.08
Ex Dividend Date: None
Dividend Date: None
Shares Outstandig: 116 M
Return on Equity (TTM): -10.10%
Current Price: $15.7
Previous Close: $15.89
52 Week Low: $6.78
52 Week High: $17.7
Earning Date (within 30 days): N/A
50 Day MA: $13.09
200 Day MA: $11.52
Link to Yahoo (Key Statistics): TXG
Link to Yahoo (Analysis): TXG
Link to Yahoo (Summary): TXG
Advertisement
Advertisement
 
* Note: Prices are in Million (M) USD.
Description:
10X Genomics Inc (TXG)
10X Genomics, Inc. is a leading life science technology firm specializing in transformational genomic analysis solutions that enable researchers to explore complex biological systems with unprecedented detail. Headquartered in Pleasanton, California, the company offers a comprehensive range of cutting-edge instruments, consumables, and analytical software designed to enhance the precision and depth of genetic research. With a robust presence in North America, Europe, and Asia, 10X Genomics is dedicated to advancing genomic technologies, making it a pivotal force in the rapidly evolving field of biological research and discovery. The company's innovative capabilities are instrumental in addressing the dynamic requirements of the life sciences sector.
These criteria used Company's Cash, EBITDA and Debt balance to determines its fair value:
Cash : $433 M
Debt : $11 M
EBITDA : $-31 M

Since Ebitda is less than 0, 0 points assigned.
This criteria used industry in which company operates:
Sector: Health information services
Industry: Healthcare

Based on industry, 3 points assigned.
This criteria used Company's Price To Earning (P/E) Ratio to determines its fair value:
Message: Cannot calculate PE Ratio since EPS is either 0 or negative.

Using default values for calculation.
Forward PE Ratio (using default values): 20.00

Since Forward PE Ratio is between 20 - 25, 2 points assigned.
This criteria used Company's ability to convert Sales into free cash flow to determine fair value:
Using last 8 overlapping fiscal years (max 20).
Average Free Cash Flow: $-90 M
Average Revenue: $375 M
Revenue Converted To Free Cash Flow (%): -24.0%

Since Free Cash Flow (FCF) to Revenue percentage is non-positive, 0 point assigned.
This criteria used company's growth potential to calculate its fair value:
Latest Revenue (2024-12-31): $611 M
Revenue 5 Years Ago (2019-12-31): $246 M
Total Growth over 5 Years: 148.4%
5-Year Revenue CAGR (Historical): 20.0%
Forward 5-Year CAGR (Tapered): 14.0%

Since historical Revenue CAGR is between 15 - 20, 4 points assigned.
This criteria used Company's ability to buy back its own share:
Latest Share Count (2024-12-31): $120 M
Share Count 5 Years Ago (2020-12-31): $101 M

Company is not buying back its own shares, 0 points assigned.
This criteria used Company's dividend payout ratio to determine its fair value:
Next Year Earnings Per Share (EPS): $-0.41
Trailing 12-Month Earnings Per Share (EPS): $0.00
Average Earnings Per Share (EPS): $0.00
Dividend Per Share (DPS): $0
Payout Ratio: 0%
Dividend Yield: 0.00%

⚠️ Caution: Negative earnings detected — Further research is recommended
  • Next Fiscal Yr EPS: $-0.41

Since Dividend Per Share is less than or equal to 0, 0 point assigned.

Since Dividend Yield is less than 1, 0 point assigned.
This criteria used Company's Return On Equity (ROE%) to determine its fair value:
Using last 6 valid ROE years (max 20).
Average ROE: -28.1%

Since Average ROE is non-positive, 0 point assigned.
This criteria used Company's current price to its 52 week low price to determines its fair value:
Current Price: $15.7
52-Week Low: $6.78
Threshold Price (15% Above 52-Week Low): $7.80

Since Current price is not within 15% threshold, 0 point assigned.
This criteria used Company's Market Cap to determines its fair value:
Market Capitalization: $2,070 M

Since Market Cap is less than 10B, 1 point assigned.
% Exposure to Total Portfolio
Based on the market cap, we recommend do not exceed 2% exposure of Total Portfolio.
Warren Buffett's Owners' Earnings:
Owners' Earnings (FCF/Share) (TTM ending 2025-09-30): $0.68
Note: Many fast-growing companies reinvest heavily, so Owners' Earnings may appear low. Consider other factors in your valuation.
Value-Trade has assigned 10 points to above 10X Genomics Inc (TXG) stock.
Fair Value PE 12, Industry Based PE 15, Growth Based PE 15, Risk-Free Anchored PE (25% MoS) 18.47. Based on these 4 values, average assigned is 15.12. The fair value of 10X Genomics Inc (TXG) stock cannot be calculated since EBITDA and EPS are either 0 or negative.

Share this valuation:


Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement